Medivir Interim Report 1 Jan - 31 Mar 2004

MEDIVIR INTERIM REPORT 1 January - 31 March 2004 · The Board of Medivir AB decided on 15 March 2004 to conduct a new share issue of approximately SEK 322m. The decision is conditional on approval by the shareholders' meeting. · A candidate drug was selected in the Cathepsin S research program against autoimmune disorders at the end of March. · An EU patent was granted in late March on Medivir's herpes project ME-609. · One more program, HCV polymerase in Medivir's preclinical research, has reached project status in the quarter. · Net sales amounted to SEK 4.9 (43.4 including CCS and 1.5 excluding CCS) m in the period. · The loss after tax was SEK -45.3 (-38.6 incl. CCS and -47.1 excl. CCS) m. Earnings per share were SEK -5.27 (-4.50). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)8 546 83100 or +46 (0)70 853 7292. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/04/22/20040422BIT00670/wkr0001.doc http://www.waymaker.net/bitonline/2004/04/22/20040422BIT00670/wkr0002.pdf